Women’s health bill
Executive Summary
Senate Health Committee passes "Women's Health Improvement Act" (S 2328) by voice vote Sept. 5. Bill includes amended version of Sen. Tom Harkin's (D-Iowa) pregnancy legislation, which would have directed FDA to enhance pregnancy drug labeling and would have given the agency authority to require postmarketing studies in pregnant women (1"The Pink Sheet" July 29, p. 11). No drug-related language is included in the final bill...
You may also be interested in...
Pediatric Exclusivity Expansion Floated On Hill; Mandatory Study Bill Pending
An additional three months of exclusivity would be awarded for a company's second round of pediatric studies under a proposed amendment to Sen. Hillary Rodham Clinton's (D-N.Y.) bill to codify FDA's mandatory pediatric study rule
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.